Innova Captab Ltd's Q3FY25 Quarter Results
- 06 Feb 2025
Result Summary
- Innova Captab Ltd reported a 0.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.2%.
- Its expenses for the quarter were up by 0.6% QoQ and 2.1% YoY.
- The net profit decreased 2.3% QoQ and increased 36.1% YoY.
- The earnings per share (EPS) of Innova Captab Ltd stood at 6 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 320.79 | 320.42 | 304.82 | 0.1% | 5.2% |
Total Expenses | 275.20 | 273.61 | 269.62 | 0.6% | 2.1% |
Profit Before Tax | 45.59 | 46.81 | 35.20 | -2.6% | 29.5% |
Tax | 11.38 | 11.80 | 10.08 | -3.6% | 12.9% |
Profit After Tax | 34.20 | 35.00 | 25.13 | -2.3% | 36.1% |
Earnings Per Share | 6.00 | 6.10 | 4.40 | -1.6% | 36.4% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Innova Captab Ltd is a company operating within the pharmaceutical sector. It specializes in the manufacturing and distribution of a wide range of pharmaceutical products. The company's product portfolio is likely to include formulations such as tablets, capsules, and syrups, catering to various therapeutic segments. As of the latest available information, there are no additional major developments or recent news specifically related to Innova Captab Ltd within the provided data. The company’s operations are focused on delivering quality pharmaceutical products to meet consumer needs in the healthcare industry.
Revenue
During the third quarter of fiscal year 2025 (Q3FY25), Innova Captab Ltd reported a total income of ₹320.79 crores. This represents a marginal increase of 0.1% quarter-over-quarter (QoQ) compared to ₹320.42 crores in Q2FY25. Year-over-year (YoY), there was a more significant increase of 5.2% from ₹304.82 crores in Q3FY24. These figures suggest a steady growth in revenue over the past year, maintaining a consistent upward trajectory. The revenue performance reflects the company's ability to sustain its market presence and possibly expand its share within the pharmaceutical industry.
Profitability
In Q3FY25, Innova Captab Ltd recorded a profit before tax of ₹45.59 crores, which showed a decrease of 2.6% QoQ from ₹46.81 crores in Q2FY25. However, there was a notable increase of 29.5% YoY compared to ₹35.20 crores in Q3FY24. The profit after tax for Q3FY25 was ₹34.20 crores, marking a slight decline of 2.3% QoQ from ₹35.00 crores in the previous quarter. Nonetheless, it represented a substantial growth of 36.1% YoY from ₹25.13 crores in Q3FY24. The earnings per share stood at ₹6.00, experiencing a minor decrease of 1.6% QoQ but a significant rise of 36.4% YoY. The profitability metrics indicate a robust year-over-year improvement despite minor quarter-over-quarter declines.
Operating Metrics
The total expenses for Innova Captab Ltd in Q3FY25 were ₹275.20 crores, which increased by 0.6% QoQ from ₹273.61 crores in Q2FY25 and by 2.1% YoY from ₹269.62 crores in Q3FY24. The tax expense for the quarter was ₹11.38 crores, a decrease of 3.6% QoQ from ₹11.80 crores but an increase of 12.9% YoY from ₹10.08 crores. The financial data highlights stable expense management with modest increases over the comparative periods. Such trends in operating expenses and tax liabilities are essential for understanding the company's operational efficiency and cost control measures over time.
